Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Medarex announces research agreement with Mitsubishi Pharma
June 2007
SHARING OPTIONS:

PRINCETON, N.J.óLate last month, Medarex Inc. announced a collaborative research agreement with Mitsubishi Pharma Corp., a subsidiary of Mitsubishi Chemical Holdings Corp. The two companies expect to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for the potential treatment of autoimmune diseases.
 
The companies plan to use Medarex's UltiMAb Human Antibody Development System to generate antibodies for research and possible development. Under the terms of the agreement, Medarex and Mitsubishi Pharma will share research responsibilities for any antibodies generated through the collaboration. Other terms of the agreement were not disclosed.
 
"We will gain access to excellent expertise that provides us with the potential advancement of novel therapeutics for autoimmune diseases," says Dr. Tohru Nakajima, executive officer/division manager of the pharmaceutical research division for Mitsubishi Pharma.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.